NCT03524235 - Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

November 7, 2021

Study Completion Date

November 6, 2024

Conditions

Multiple MyelomaCLLChronic Lymphocytic LeukemiaLymphomaHodgkin Lymphoma

Interventions

RADIATION

Total Body Irradiation

Pre-Transplantation Total Body Irradiation

PROCEDURE

Haploidentical Stem Cell Transplantation

BIOLOGICAL

CD56-Enriched Donor Lymphocyte Infusion

DRUG

Bendamustine

Pre-Transplantation Bendamustine

DRUG

Fludarabine

Pre-Transplantation Fludarabine

DRUG

Rituximab

Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)

Trial Locations (1)

Cedars Sinai Medical Center, Los Angeles